Effects of additive therapy of losaretan in chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201103166080N1

Enrollment

Registered

2012-03-09

Start date

2011-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease. Other chronic obstructive pulmonary disease

Interventions

Intervention 1: Treatment group: 12.5 milligram losaretan, twice daily for 1 months, and if it is tolerated and creatinine does not raise, it is continuing with 25 milligram for 3 months. Intervention

Treatment - Drugs

Placebo

Treatment group: 12.5 milligram losaretan, twice daily for 1 months, and if it is tolerated and creatinine does not raise, it is continuing with 25 milligram for 3 months.

Control group: placebo, twice daily for 4 months

Eligibility

Sex/Gender

All

Age

35 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: history of chronic obstructive lung disease base on spirometry data and clinical sign and symptoms referred by pulmonologist. Exclusion criteria: congestive heart failure; myocardial infarction in 6 months ego; consumption of angiotensine converting enzyme inhibitors and angiotensine receptor blockers; dehydration; renal artery stenosis; hyperkalemia; uncontrolled hypertension; allergy to losaretan.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FVC-percent of forced vital capacity. Timepoint: 4months. Method of measurement: By spirometer.;FEV1—Forced expiratory volume in one second percent of. Timepoint: 4 month. Method of measurement: By spirometr.;Hematocrit. Timepoint: 4 month. Method of measurement: Percent and by coulter sysmex.;Fev1/fvc. Timepoint: 4 months. Method of measurement: By spirometer.;FEF25%-75%. Timepoint: 4months. Method of measurement: By spirometer.;Severity of dyspnea. Timepoint: 4 months. Method of measurement: Grade and by modified medical research council-MMRC Scale.	—

Measure

Time frame

FVC-percent of forced vital capacity. Timepoint: 4months. Method of measurement: By spirometer.;FEV1—Forced expiratory volume in one second percent of. Timepoint: 4 month. Method of measurement: By spirometr.;Hematocrit. Timepoint: 4 month. Method of measurement: Percent and by coulter sysmex.;Fev1/fvc. Timepoint: 4 months. Method of measurement: By spirometer.;FEF25%-75%. Timepoint: 4months. Method of measurement: By spirometer.;Severity of dyspnea. Timepoint: 4 months. Method of measurement: Grade and by modified medical research council-MMRC Scale.

—

Secondary

Measure	Time frame
Raising of creatinine. Timepoint: 1 month. Method of measurement: laboratory.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mehdi Bakhtiar

Arak University of medical sciences

Mehdi-bakhtiar@yahoo.co.uk+98 86 1417 3608

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026